Kringle Pharma (4884) · RiskRestated
Loss of competitive advantage through leakage of manufacturing technology and know-how
First written in FY2020. 1 of 2 entries say "Restated". Latest entry: FY2022.
2entries
3years
0from disclosures
How it moved
Same theme, other companies
Risk of weakened protection of the company's intellectual property and manufacturing know-howA theme 20 companies write about · 20 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2024: 3 of 7 companies on the "Worse" side.
11 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 20 companies compared. The sentences above are computed from all 20.Full recordFilings, disclosures and news, newest first
- FY2022RestatedAnnual report
「If manufacturing technology or know-how were to leak for any reason, our manufacturing advantage could be lost and other companies could manufacture the products.」
製造方法を特許出願せずノウハウとして管理する方針に伴う流出リスクを再掲している。 - FY2020First statedAnnual report
「If manufacturing technology or know-how were to leak for any reason, our manufacturing advantage could be lost and other companies could manufacture the products.」
The company protects its manufacturing methods as undisclosed know-how rather than filing patent applications, while identifying leakage and the resulting loss of advantage as a risk.